Kyle Piskel serves as the Chief Financial Officer at Adaptive Biotechnologies Corp, a pioneering company in the field of immune-driven medicine. With a robust background in finance and biotechnology, Piskel has been instrumental in steering the company towards financial stability and growth. Prior to joining Adaptive Biotechnologies, he held significant roles at leading financial institutions and biotech firms, where he honed his expertise in financial strategy and corporate development. At Adaptive Biotechnologies, Piskel's primary responsibilities include overseeing the company's financial operations, strategic planning, and investor relations. His strategic vision has been pivotal in guiding the company through various stages of growth, including successful fundraising efforts and the expansion of its product portfolio. Under his leadership, Adaptive Biotechnologies has strengthened its position in the market, enabling the company to advance its mission of transforming the diagnosis and treatment of diseases through immune system analysis. Piskel's achievements extend beyond his role at Adaptive Biotechnologies. He is recognized in the industry for his contributions to financial management and strategic planning in the biotech sector. His ability to navigate complex financial landscapes and his commitment to innovation have made him a respected figure among peers and a key asset to the company. Through his leadership, Adaptive Biotechnologies continues to make significant strides in the development of groundbreaking immune-driven therapies.